Activated Clotting Time [ACT] | 合法醫療器材資訊網

2021年4月27日—Theactivatedclottingtimefirstcameintoclinicaluseinthemid-1970stoguidetheadministrationandreversalofheparinduringcardiopulmonary ...

Activated Clotting Time [ACT]

The Activated Clotting Time (ACT) was first described by Hattersley in 1966 and is essentially a point of care test (POCT) of coagulation that is used to monitor the anticoagulant effect of unfractionated heparin (UFH) in patients on cardio-pulmonary bypass, on ECMO [extracorporeal membrane oxygenation], undergoing percutaneous transluminal coronary angioplasty, on haemofiltration or haemodialysis. In the early days of cardio-pulmonary bypass (CPB) the dose of Heparin used to prevent clotting in the extra-corporeal circuit was established empirically – the dose being the minimum in which clotting in the extracorporeal circuit did not occur. The minimum safe ACT is in the region of 300 seconds based upon observations that above this level blood clots rarely occur in the extracorporeal circuit. In most cases of CPB – a dose of UFH in the regi...